Blood-thinning medicine to prevent clots during pancreatic cancer treatment
Tests extra clot prevention in people with pancreatic cancer receiving pre-surgery treatment.
Plain-language title generated from the registry record
Registry title: Prevention of thromboembolism during pancreatic cancer treatments - link to prognosis and relapse of the disease.
Key facts
- Where
- Helsinki, Oulu, Tampere, and Turku, FinlandSee the 4 sites
- Phase
- Phase 4
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with pancreatic cancer who are about to start treatment before surgery (neoadjuvant treatment). It studies blood-clot prevention during that treatment.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Pancreatic cancer, with treatment before surgery (neoadjuvant treatment) being planned.
- Earlier treatment
- Must not already be taking blood-thinning (anticoagulant) medicine.
Main reasons for not taking part
- Cannot use tinzaparin (a blood thinner) for medical reasons
- Already taking blood-thinning (anticoagulant) medicine
- Another active cancer in the past five years
- Severe kidney failure
- Tendency to bleed
Read by machine on 9 November 2026.
Where in Finland
- HUS-YhtymaeHelsinki, FinlandTaking people
- Oulu University HospitalOulu, FinlandTaking people
- Tampere University HospitalTampere, FinlandTaking people
- Turku University HospitalTurku, FinlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorTrial details
- Who runs it
- HUS-Yhtymae
- Trial code
- EU 2024-512475-12-01
- Record updated
- 27 November 2024
- Original description
Neoadjuvant-treated pancreatic cancer patients are at increased risk of thrombosis. Our aim is to investigate the impact of thromboprophylaxis administered during neoadjuvant treatments on the risk of vascular events and survival prognosis in pancreatic cancer patients in a randomized prospective study.Read full original descriptionShow less
Thrombosis prophylaxis and coagulation activation during neoadjuvant treatment in pancreatic cancer - Association to prognosis and recurrence.
Neoadjuvant-treated pancreatic cancer patients are at increased risk of thrombosis. Our aim is to investigate the impact of thromboprophylaxis administered during neoadjuvant treatments on the risk of vascular events and survival prognosis in pancreatic cancer patients in a randomized prospective study.
Inclusion: An adult pancreatic cancer patient for whom neoadjuvant treatments are being planned due to pancreatic cancer.
Exclusion: The study excludes patients, if they have contraindications for using tinzaparin, are already on anticoagulant medication, have had any other active cancer in the past five years or have severe kidney failure or bleeding tendencies.